Literature DB >> 7792733

Effects of two different doses of hirudin on APTT, determined with eight different reagents.

M Monreal1, L Monreal, R Ruiz de Gopegui, Y Espada, A M Angles, J Monasterio.   

Abstract

The APTT has been considered the most suitable candidate to monitor the anticoagulant activity of hirudin. However, its use is hampered by problems of standardization, which make the results heavily dependent on the responsiveness of the reagent used. Our aim was to investigate if this different responsiveness of different reagents when added in vitro is to be confirmed in an ex vivo study. Two different doses of r-hirudin (CGP 39393), 0.3 mg/kg and 1 mg/kg, were administered subcutaneously to 20 New Zealand male rabbits, and the differences in prolongation of APTT 2 and 12 h later were compared, using 8 widely used commercial reagents. All groups exhibited a significant prolongation of APTT 2 h after sc administration of hirudin, both at low and high doses. But this prolongation persisted 12 h later only when the PTTa reagent (Boehringer Mannheim) was used. In general, hirudin prolonged the APTT most with the silica-based reagents. In a further study, we compared the same APTT reagents in an in vitro study in which normal pooled plasma was mixed with increasing amount of hirudin. We failed to confirm a higher sensitivity for silica-containing reagents. Thus, we conclude that subcutaneous administration of hirudin prolongs the APTT most with the silica-based reagents, but this effect is exclusive for the ex vivo model.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7792733

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  2 in total

Review 1.  Pharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin.

Authors:  M Monreal; J Costa; P Salva
Journal:  Drugs Aging       Date:  1996-03       Impact factor: 3.923

2.  Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease.

Authors:  M Cullberg; U G Eriksson; M Larsson; M O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.